KRAS and cancer: ARS-1620 (a potent, orally bioavailable covalent inhibitor of KRAS c.34G > T (p.G12C), when combined with alisertib (AURKA inhibitor), was observed to have a significant synergistic effect in ARS-1620-refractory KRAS c.34G > T (p.G12C) mutant cancer.